HSCA Applauds House Energy and Commerce Committee and Senate HELP Committee for Advancing Bipartisan Biosimilars Legislation that Will Help Increase Access to Safe Medications

Washington, D.C. (July 29, 2026) – The Healthcare Supply Chain Association (HSCA) and its traditional healthcare group purchasing organization (GPO) members commend the U.S. House Committee on Energy and Commerce for unanimously advancing two bipartisan bills that would expand patient access to lower-cost biosimilars: the Expedited Access to Biosimilars Act (H.R. 9661), led by Reps. Nick Langworthy (R-NY) and Kim Schrier (D-WA), and the Biosimilar Red Tape Elimination Act (H.R. 5526), led by Reps. August Pfluger (R-TX) and Greg Landsman (D-OH). This comes after the Senate Health, Education, Labor, and Pensions (HELP) Committee’s recent advancement of two companion bills, the Expedited Access to Biosimilars Act (S.1414), led by Sen. Rand Paul (R-KY), and the Biosimilars Red Tape Elimination Act (S.1954), led by Sens. Mike Lee (R-UT) and Ben Ray Lujan (D-NM).

 

“Biosimilars are one of the most effective tools for expanding generic competition in the prescription drug marketplace. Biosimilars have the potential to increase patient access to life-saving medications and reduce costs for the entire healthcare system,” said HSCA President and CEO Angie Boliver. “HSCA has long advocated for policies that ensure a pathway to market for biosimilars that prioritize patient safety while encouraging development and uptake. Eliminating outdated, duplicative testing requirements will help patients get faster access to safe, affordable treatments.”

 

Click here to view the full statement.